American Journal of Biomedical and Life Sciences 2015; 3(2): 16-24 Published online April 9, 2015 (http://www.sciencepublishinggroup.com/j/ajbls) doi: 10.11648/j.ajbls.20150302.12 ISSN: 2330-8818 (Print); ISSN: 2330-880X (Online) Investigation of In-Vivo Neuropharmacological and In-Vitro Thrombolytic Activity & Phytochemical Analysis of Ethanolic Extract of Argyria Captiformis Leaves Saiful Islam * , Naymul Karim, Imam Hasan, Md Hossan Sakib, Md. Harun-Or- Rashid, Sadequr Rahman, Masudur Rahman Department of Pharmacy, International Islamic University Chittagong, Chittagong, Bangladesh Email address: saifuliiucpharmacy@gmail.com (S. Islam), naiemph@gmail.com (N. Karim), hasanrajbp@yahoo.com (I. Hasan), sakibiiucph@gmail.com (Md. H. Sakib), haruniiucph@gmail.com (Md. Harun-Or-Rashid), sadeqpharm@yahoo.com (S. Rahman), mamun2001@hotmail.com (M. Rahman) To cite this article: Saiful Islam, Naymul Karim, Imam Hasan, Md Hossan Sakib, Md. Harun-Or- Rashid, Sadequr Rahman, Masudur Rahman. Investigation of In-Vivo Neuropharmacological and In-Vitro Thrombolytic Activity & Phytochemical Analysis of Ethanolic Extract of Argyria Captiformis Leaves. American Journal of Biomedical and Life Sciences. Vol. 3, No. 2, 2015, pp. 16-24. doi: 10.11648/j.ajbls.20150302.12 Abstract: Objectives: Investigation with the crude ethanolic extract of Argyria captiformis leaves was carried out to evaluate its possible thrombolysis and to analyze in –vivo neuro-pharmacological effects as anxiety is a particular form of behavioral inhibition that occurs in response to novel environment events and also phytochemical screening of plant extract. Method: Ethanolic extract of Argyria captiformis Leaves was assessed for sedative and anxiolytic activity on Swiss albino mice and Thrombolytic activity was assessed with human blood and also phytochemical screening test was done by various chemical reagents. Sedative activity was evaluated by using hole cross, open field, thiopental sodium-induced sleeping time and anxiolytic property was evaluated by elevated-plus maze(EPM) tests at 400mg/kg while the peripheral and thrombolytic activity determined by percentage of clot lysis. Result: In anxiolytic study, the extract displayed increased percentage of entry into open arm at the dose of 400mg/kg. The extract produced a significant (P<0.01) increase in sleeping duration and reduction of onset of sleep compared to sodium thiopental at doses (400 mg/kg) .The extract (400 mg/kg) also showed suppression of motor activity and exploratory activity of the mice in both open field and hole cross test. Argyria captiformis alone & Argyria captiformis in combination with Streptokinase demonstrated 38.19±4.76% & 77.45±2.97% clot lysis effect respectively & revealed significant with comparison to both the control agent. The presence of tannins, glycosides, saponins, flavonoids, cardiac glycosides, and phytosterols was determined. Conclusion: The pharmacological profiles of the present investigation of the ethanol extract of A. captiformis indicate that the extract possess good CNS depressant and exhibited considerable thrombolytic as it significantly reduced locomotion, onset of sleep, increased duration of sleep and also presence of, glycosides, cardiac glycosides, saponins, flavonoids ,tannins and phytosterols. Keywords: Sedative and Anxiolytic Activity, Phytochemical, Argyria Captiformis, Thrombolytic Activity, % Lysis of Clot 1. Introduction Anxiety and depression are the most common psychiatric disorders. Over 20% of the adult population suffers from these illnesses at some time during their lives [1-3] . It has become an important area of research interest in psychopharmacology during this decade [4] . Benzodiazepines are among the most prescribed and effective antianxiety drugs used worldwide [5]. But these are being slowly replaced by antidepressants, which are not only efficacious in depression, but also in the acute and long-term Treatment of several anxiety disorders [6]. Consumption of these drugs is believed to double every five years [7]. Most of these drugs, however, have an unfavorable risk and benefit ratio, and their prominent side effects still represent a barrier to long-term treatment with these drugs [8] . In addition, the risk of interaction with other substances is high, particularly with alcohol [9] . Hence, there is an urgent need to search for newer, better-tolerated, and more efficacious therapeutic agents, for better management of anxiety and depression.